Clinical trials: Hodgkin Disease Lymphoma
Lymphoma
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00907036
- Testing
- alemtuzumab, donor lymphocytes, cyclosporine
- Volunteers
- 49 people
- Sponsor
- Cancer Research UK
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine…
- Trial name
- NCT02596971
- Testing
- Atezolizumab, Bendamustine, Cyclophosphamide
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, B Cell Lymphoma
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
- Conditions
- Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
- Trial name
- CAR-T，MTD (NCT07048353)
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Diffuse Large B-Cell Lymphoma
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
The primary objective of the protocol is to estimate the complete response rate of three courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell…
- Trial name
- NCT00842595
- Testing
- rituximab, vinorelbine, ifosfamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- French Innovative Leukemia Organisation
Diffuse Large B-cell Lymphoma
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Patients initially are randomized into 2 arms: Arm I: R-DA-EPOCH; Arm II: R-CEOP90; Patients who achieved complete remission (CR) or partial remission (PR) after 6 cycles of R-DA-EPOCH (Arm I) or R-CEOP90 (Arm II), continue to…
- Trial name
- NCT03213977
- Testing
- R-DA-EPOCH, R-CEOP90
- Where
- China
- Volunteers
- 475 people
- Sponsor
- Fujian Medical University
Hodgkin Lymphoma
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
The choice of a preferred first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related effects.
- Trial name
- NCT01251107
- Testing
- Bleomycin, Etoposide, Doxorubicin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- Fondazione Michelangelo
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Mediastinal Lymphoma, Hodgkin Disease Lymphoma
Proton Therapy for Mediastinal Lymphoma (PROMLY)
The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.
- Conditions
- Mediastinal Lymphoma, Hodgkin Disease Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
- Trial name
- PROMLY (NCT07817641)
- Testing
- Proton therapy
- Where
- Denmark
- Volunteers
- 139 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Chronic Lymphocytic Leukemia (CLL)
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell…
- Trial name
- NCT01466153
- Testing
- Rituximab, Bendamustine, MEDI-551
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 183 people
- Sponsor
- MedImmune LLC
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non-hodgkins Lymphoma, Hodgkins Lymphoma
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
This is an exploratory study to study the efficacy of combination regimen of Oncaspar/Doxil/Decadron (ODD) in patients with refractory lymphoid malignancies.
- Conditions
- Non-hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma
- Trial name
- NCT00837200
- Testing
- Oncaspar, Doxil, Decadron
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Milton S. Hershey Medical Center
T-cell NHL (PTCL or CTCL)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
- Trial name
- NCT07192471
- Testing
- KK2223
- Where
- 22 sites in United States, Italy and 1 more
- Volunteers
- 72 people
- Sponsor
- Kyowa Kirin, Inc.
Cancer, Lymphomas
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma whose disease had progressed after treatment with standard, approved therapies that included 2 stages.
- Trial name
- NCT00396864
- Testing
- NPI-0052
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Celgene
Math Learning Disability, Child Development
Interventions in Mathematics and Cognitive Skills
The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning…
- Conditions
- Math Learning Disability, Child Development, Developmental Disability, Learning Disabilities
- Trial name
- NCT05201534
- Testing
- Interventions in Mathematics and Cognitive Skills - Experimental, Interventions in Mathematics and Cognitive Skills - Active Comparator
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Stanford University
Diffuse Large Cell Lymphoma, Lymphoma
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and…
- Trial name
- NCT00591630
- Testing
- Zevalin, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Indolent Non-follicular, Non-Hodgkin's Lymphoma
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with advanced untreated Indolent non Follicular…
- Trial name
- IIL INFL09 (NCT01929265)
- Testing
- Bendamustine
- Where
- 25 sites in Italy
- Volunteers
- 73 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma, Non-Hodgkin
Copanlisib Chinese PK Study
This study will be conducted primarily to determine the pharmacokinetics of copanlisib in Chinese patients with relapsed iNHL. The primary objective of the study is to determine the pharmacokinetics of copanlisib administered on…
- Trial name
- NCT03498430
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Bayer
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. Five-year PFS and OS for these patients received classic CHOP regimen (cyclophosphamide, vincristin, doxorubicin and prednisone) is less than…
- Conditions
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Enteropathy Associated T Cell Lymphoma
- Trial name
- NCT02533700
- Testing
- CEOP/IVE/GDP chemotherapy regimen, CEOP chemotherapy regimen for 6 cycles
- Where
- 4 sites in China
- Volunteers
- 106 people
- Sponsor
- Shandong Provincial Hospital
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004084
- Testing
- indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.